X
CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19). Learn More

Abiraterone Acetate (Zytiga®)

 
Common name: Abiraterone Acetate
Brand name: Zytiga®


What is Abiraterone Acetate?

Abiraterone Acetate is a drug used to treat advanced prostate cancer (metastatic castrate resistant prostate cancer). Abiraterone acetate blocks the production of testosterone to stop the spread and growth of prostate cancer cells.

Abiraterone Acetate is used in combination with a corticosteroid (such as prednisone) and has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy after failure of androgen deprivation therapy.
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.


How is Abiraterone Acetate administered?

Abiraterone Acetate is administered orally as a tablet.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received abiraterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Frequent urination
  • High blood pressure
  • Hot flashes
  • Joint pain
  • Low potassium (hypokalemia)
  • Muscle aches
  • Upset stomach

Is Abiraterone Acetate covered in my province or territory?

Abiraterone acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Abiraterone acetate is not covered by provincial/territorial drug programs in:
  • Manitoba
  • Prince Edward Island
  • Nunavut
  • Northwest Territories
  • Yukon
The pan-Canadian Oncology Drug Review (pCODR) recommends funding abiraterone acetate (zytiga®).
To read pCODRs full recommendation, please click here.

For more information on pCODR, please visit www.pcodr.ca
 


Last Reviewed: July 2017
Prostate Cancer Canada and Canadian Cancer Society








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.
More

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More


Click here for news archive